Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance

Protein Expression and Purification

Volumn 70, Issue 1, 2010, Pages 32-38

  Papakostas, Thanos D ^a   Pieretti Vanmarcke, Rafael ^b   Nicolaou, Fotini ^b   Thanos, Aristomenis ^a   Trichonas, George ^a   Koufomichali, Xanthi ^a   Anago, Kosisochukwu ^b   Donahoe, Patricia K ^b   Teixeira, Jose ^b   MacLaughlin, David T ^b   Vavvas, Demetrios ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bioactivity; FLAG tag; Mullerian Inhibiting Substance (MIS); Purification

Indexed keywords

FLAG PEPTIDE; HYBRID PROTEIN; MUELLERIAN INHIBITING FACTOR; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTI-MULLERIAN HORMONE; BLOTTING, WESTERN; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 75349100108     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.09.004     Document Type: Article

References (29)

1. Cohen-Haguenauer O., Picard J.Y., Mattei M.G., Serero S., Nguyen V.C., de Tand M.F., Guerrier D., Hors-Cayla M.C., Josso N., and Frezal J. Mapping of the gene for anti-mullerian hormone to the short arm of human chromosome 19. Cytogenet. Cell Genet. 44 (1987) 2-6
2. Baker M.L., Metcalfe S.A., and Hutson J.M. Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J. Clin. Endocrinol. Metab. 70 (1990) 11-15
3. Hudson P.L., Dougas I., Donahoe P.K., Cate R.L., Epstein J., Pepinsky R.B., and MacLaughlin D.T. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J. Clin. Endocrinol. Metab. 70 (1990) 16-22
4. Wang P.Y., Koishi K., McGeachie A.B., Kimber M., Maclaughlin D.T., Donahoe P.K., and McLennan I.S. Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc. Natl. Acad. Sci. USA 102 (2005) 16421-16425
5. MacLaughlin D.T., and Donahoe P.K. Mullerian inhibiting substance: an update. Adv. Exp. Med. Biol. 511 (2002) 25-38 (discussion 38-40)
6. Nachtigal M.W., and Ingraham H.A. Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc. Natl. Acad. Sci. USA 93 (1996) 7711-7716
7. MacLaughlin D.T., Hudson P.L., Graciano A.L., Kenneally M.K., Ragin R.C., Manganaro T.F., and Donahoe P.K. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology 131 (1992) 291-296
8. Pepinsky R.B., Sinclair L.K., Chow E.P., Mattaliano R.J., Manganaro T.F., Donahoe P.K., and Cate R.L. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J. Biol. Chem. 263 (1988) 18961-18964
9. Ragin R., Donahoe P., Kenneally M., Ahmad M., and MacLaughlin D. Human mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr. Purif. 3 (1992) 236-245
10. Kurian M., de la Cuesta R., Waneck G., MacLaughlin D., Manganaro T., and Donahoe P. Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo. Clin. Cancer Res. 1 (1995) 343-349
11. Imbeaud S., Carre-Eusebe D., Rey R., Belville C., Josso N., and Picard J.Y. Molecular genetics of the persistent mullerian duct syndrome: a study of 19 families. Hum. Mol. Genet. 3 (1994) 125-131
12. Clarke T., Hoshiya Y., Yi S., Liu X., Lyons K., and Donahoe P. Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol. Endocrinol. 15 (2001) 946-959
13. Gouedard L., Chen Y., Thevenet L., Racine C., Borie S., Lamarre I., Josso N., Massague J., and di Clemente N. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J. Biol. Chem. 275 (2000) 27973-27978
14. He W.W., Gustafson M.L., Hirobe S., and Donahoe P.K. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev. Dyn. 196 (1993) 133-142
15. Zhan Y., Fujino A., MacLaughlin D.T., Manganaro T.F., Szotek P.P., Arango N.A., Teixeira J., and Donahoe P.K. Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. Development 133 (2006) 2359-2369
16. Baarends W.M., Hoogerbrugge J.W., Post M., Visser J.A., De Rooij D.G., Parvinen M., Themmen A.P., and Grootegoed J.A. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology 136 (1995) 5614-5622
17. Baarends W.M., van Helmond M.J., Post M., van der Schoot P.J., Hoogerbrugge J.W., de Winter J.P., Uilenbroek J.T., Karels B., Wilming L.G., Meijers J.H., et al. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120 (1994) 189-197
18. di Clemente N., Wilson C., Faure E., Boussin L., Carmillo P., Tizard R., Picard J.Y., Vigier B., Josso N., and Cate R. Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol. Endocrinol. 8 (1994) 1006-1020
19. Teixeira J., He W.W., Shah P.C., Morikawa N., Lee M.M., Catlin E.A., Hudson P.L., Wing J., Maclaughlin D.T., and Donahoe P.K. Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 137 (1996) 160-165
20. Arango N.A., Kobayashi A., Wang Y., Jamin S.P., Lee H.H., Orvis G.D., and Behringer R.R. A mesenchymal perspective of Mullerian duct differentiation and regression in Amhr2-lacZ mice. Mol. Reprod. Dev. 75 (2008) 1154-1162
21. Pieretti-Vanmarcke R., Donahoe P.K., Szotek P., Manganaro T., Lorenzen M.K., Lorenzen J., Connolly D.C., Halpern E.F., and MacLaughlin D.T. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin. Cancer Res. 12 (2006) 1593-1598
22. Masiakos P.T., MacLaughlin D.T., Maheswaran S., Teixeira J., Fuller Jr. A.F., Shah P.C., Kehas D.J., Kenneally M.K., Dombkowski D.M., Ha T.U., Preffer F.I., and Donahoe P.K. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin. Cancer Res. 5 (1999) 3488-3499
23. Barbie T.U., Barbie D.A., MacLaughlin D.T., Maheswaran S., and Donahoe P.K. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc. Natl. Acad. Sci. USA 100 (2003) 15601-15606
24. Renaud E.J., MacLaughlin D.T., Oliva E., Rueda B.R., and Donahoe P.K. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc. Natl. Acad. Sci. USA 102 (2005) 111-116
25. Segev D.L., Hoshiya Y., Hoshiya M., Tran T.T., Carey J.L., Stephen A.E., MacLaughlin D.T., Donahoe P.K., and Maheswaran S. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc. Natl. Acad. Sci. USA 99 (2002) 239-244
26. Hoshiya Y., Gupta V., Kawakubo H., Brachtel E., Carey J.L., Sasur L., Scott A., Donahoe P.K., and Maheswaran S. Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. J. Biol. Chem. 278 (2003) 51703-51712
27. Gustafson M., Lee M., Scully R., Moncure A., Hirakawa T., Goodman A., Muntz H., Donahoe P., MacLaughlin D., and Fuller A.J. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N. Engl. J. Med. 326 (1992) 466-471
28. Wang W., and Malcolm B.A. Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis. Biotechniques 26 (1999) 680-682
29. Donahoe P.K., Ito Y., and Hendren III W.H. A graded organ culture assay for the detection of Mullerian inhibiting substance. J. Surg. Res. 23 (1977) 141-148